The Efficacy and Safety of Selinexor in Combination with Ruxolitinib in Ruxolitinib-Treated Myelofibrosis Patients: the Interim Analysis of a Prospective, Open-Label, Multicenter, Parallel-Cohort, Phase 2 Study

被引：3

作者：

Duan, Minghui ^{[1
]}

Ma, Lan ^{[2
]}

Wu, Qiuling ^{[3
]}

Liang, Hong ^{[4
]}

Wang, Wei ^{[5
]}

Wu, Shaoling ^{[5
]}

Mu, Lijun ^{[6
]}

Lin, Hai ^{[7
]}

Zhou, Hebing ^{[8
]}

Shi, Hong-Xia ^{[9
]}

Wang, Jinghua ^{[10
]}

Jing, Hongmei ^{[2
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Hematol, Beijing, Peoples R China

[2] Peking Univ Third Hosp, Beijing, Peoples R China

[3] Huazhong Univ Sci & Technol, Inst Hematol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China

[4] Harbin Inst Hematol & Oncol, Dept Hematol & Oncol, Haerbin, Peoples R China

[5] Qingdao Univ, Affiliated Hosp, Dept Hematol, Qingdao, Peoples R China

[6] Dalian Med Univ, Hosp 2, Dalian, Peoples R China

[7] First Hosp Jilin Univ, Dept Hematol, Jilin, Jilin, Peoples R China

[8] Capital Med Univ, Beijing Luhe Hosp, Dept Hematol, Beijing, Peoples R China

[9] Peking Univ, Natl Clin Res Ctr Hematol Dis, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Inst Hematol,Peoples Hosp, Beijing, Peoples R China

[10] Harbin Med Univ, Affiliated Hosp 2, Harbin, Heilongjiang, Peoples R China

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-188037

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[21] A Phase 2 Study of the Safety and Efficacy of INCB050465 in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)
Daver, Naval
Dao, Kim-Hien
Assad, Albert
Verstovsek, Srdan
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S351 - S351
[22] Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50-100 x 109/L): Final Analysis of an Open-Label Phase 2 Study
Talpaz, Moshe
Prchal, Josef
Afrin, Lawrence
Arcasoy, Murat
Hamburg, Solomon
Clark, Jason
Kornacki, Deanna
Colucci, Philomena
Verstovsek, Srdan
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (05): : 336 - 346
[23] The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: An open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis
McMullin M.F.
Harrison C.N.
Niederwieser D.
Demuynck H.
Jäkel N.
Gopalakrishna P.
McQuitty M.
Stalbovskaya V.
Recher C.
Theunissen K.
Gisslinger H.
Kiladjian J.-J.
Al-Ali H.-K.
Experimental Hematology & Oncology, 4 (1)
[24] Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis
Durrant, Simon T.
Nagler, Arnon
Guglielmelli, Paola
Lavie, David
le Coutre, Philipp
Gisslinger, Heinz
Chuah, Charles
Maffioli, Margherita
Bharathy, Savita
Dong, Tuochuan
Wroclawska, Monika
Martinez Lopez, Joaquin
HAEMATOLOGICA, 2019, 104 (12) : E551 - E554
[25] Phase 2 Study to Assess the Safety and Efficacy of Bomedemstat (MK3543) in Combination with Ruxolitinib in Patients with Myelofibrosis
Gill, Harinder
Au, Lester
Leung, Garret Man Kit
Tsai, Dorothy
Yim, Rita
Chin, Lynn
Li, Vivian
Lee, Paul
Leung, Rock Yuk Yan
Lee, Elaine
Rienhoff, Hugh Young, Jr.
Kwong, Yok Lam
BLOOD, 2023, 142
[26] Safety and Efficacy of Ruxolitinib in an Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (MF): An 1144-Patient Update
Martino, Bruno
le Coutre, Philipp
Griesshammer, Martin
Illmer, Thomas
Schlag, Rudolf
Waller, Cornelius F.
Liberati, Anna Marina
Schafhausen, Philippe
Tavares, Renato S.
Vannucchi, Alessandro M.
Giraldo, Pilar
Foltz, Lynda M.
Raanani, Pia
Gupta, Vikas
Tannir, Bayane
Ronco, Julian Perez
Ghosh, Jaggannath
Al-Ali, Haifa Kathrin
BLOOD, 2014, 124 (21)
[27] Safety and Efficacy of Ruxolitinib for the Final Enrollment of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (N=2233)
Foltz, Lynda
Palumbo, Giuseppe A.
Martino, Bruno
Palandri, Francesca
Al-Ali, Haifa Kathrin
Liberati, Anna Marina
Le Coutre, Philipp D.
Vannucchi, Alessandro M.
Garcia-Hernandez, Carmen
Tavares, Renato
Griesshammer, Martin
Gupta, Vikas
Raanani, Pia
Giraldo, Pilar
Bouard, Catherine
Ronco, Julian Perez
Khanna, Sadhvi
Zaritskey, Andrey
BLOOD, 2016, 128 (22)
[28] Final Analysis of a Multicenter Pilot Phase 2 Study of Ruxolitinib and Danazol in Patients with Myelofibrosis
Gowin, Krisstina L.
Kosiorek, Heidi E.
Dueck, Amylou Constance
Mascarenhas, John
Hoffman, Ronald
Reeder, Craig B.
Camoriano, John
Fauble, Veena
Tibes, Raoul
Gano, Katherine
Ghurye, Vineta
Koenig, Patricia
Mesa, Ruben A.
BLOOD, 2015, 126 (23)
[29] Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3trial
Harrison, Claire N.
Mesa, Ruben
Talpaz, Moshe
Al-Ali, Haifa Kathrin
Xicoy, Blanca
Passamonti, Francesco
Palandri, Francesca
Benevolo, Giulia
Vannucchi, Alessandro Maria
Mediavilla, Clemence
Iurlo, Alessandra
Kim, Inho
Rose, Shelonitda
Brown, Patrick
Hernandez, Christopher
Wang, Jia
Kiladjian, Jean-Jacques
LANCET HAEMATOLOGY, 2024, 11 (10): : e729 - e740
[30] Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial
Al-Ali, Haifa Kathrin
Griesshammer, Martin
le Coutre, Philipp
Waller, Cornelius F.
Liberati, Anna Marina
Schafhausen, Philippe
Tavares, Renato
Giraldo, Pilar
Foltz, Lynda
Raanani, Pia
Gupta, Vikas
Tannir, Bayane
Ronco, Julian Perez
Ghosh, Jagannath
Martino, Bruno
Vannucchi, Alessandro M.
HAEMATOLOGICA, 2016, 101 (09) : 1065 - 1073

← 1 2 3 4 5 →